Novartis Sandostatin LAR
Executive Summary
NDA submitted May 29 for long-acting release formulation of Sandostatin (octreotide). Sandostatin LAR is a single monthly I.M. injection for treatment of acromegaly, to control symptoms of metastatic carcinoid tumors, and to control diarrhea due to vasoactive intestinal peptide-secreting tumors...